首页> 外文期刊>Gynecologic Oncology: An International Journal >Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
【24h】

Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.

机译:比较ASCUS / LSIL术后随访细胞学中检测HPV的不同商业方法,随访活检中CIN2-3的预测以及CIN2-3的自发消退。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Different Human Papilloma Virus (HPV) tests are currently used. An integrated comparison of the Amplicor, Cobas4800, PreTect HPV-Proofer and APTIMA HPV tests has not been done. METHODS: We compared the high-risk HPV detection power of these HPV tests in 528 consecutive population-based follow-up Liquid-Based Cytology samples (LBC) after ASCUS/LSIL index cytology. Their sensitivity and specificity to detect HPV in LBC, their predictive values of histopathologic CIN2-3 in follow-up punch biopsies and CIN2-3 regression in the subsequent cones was assessed. The HPV subtypes detected by the Linear Array genotyping-test (LA), PreTect HPV-Proofer and Cobas4800 were also compared. The follow-up histopathology was consensus expert-reviewed and Ki67/p16-supported. The predictive values of the HPV results in LBC by the different tests for presence of CIN2-3 in follow-up biopsies, and regression in subsequent cones, was assessed. RESULTS: Amplicor, Cobas4800 and APTIMA show good agreement for HPV-positivityegativity. PreTect HPV-Proofer has many discrepancies versus any of the other methods. The sensitivities for Amplicor, Cobas4800 and APTIMA to detect CIN2-3 were very high (96-100%), but rather low for PreTect HPV-Proofer (53%). Specificity in case of CIN1 or less in follow-up biopsies of Amplicor and Cobas4800 is lower than APTIMA and highest for PreTect HPV-Proofer. HPV subtyping by LA agreed in 90% with Cobas4800 but 70% with PreTect HPV-Proofer. CONCLUSIONS: The Amplicor, Cobas4800 and APTIMA give comparable results but PreTect HPV-Proofer differs from the other tests, with low sensitivity but higher specificity. None of the methods predicted regression of CIN2-3.
机译:目的:目前正在使用不同的人类乳头瘤病毒(HPV)测试。还没有对Amplicor,Cobas4800,PreTect HPV-Proofer和AP​​TIMA HPV测试进行综合比较。方法:我们在ASCUS / LSIL指数细胞学检查后,在528个连续的基于人群的随访液基细胞学样本(LBC)中比较了这些HPV检测的高风险HPV检测能力。评估了他们检测LBC中HPV的敏感性和特异性,其在后续打孔活检中的组织病理学CIN2-3的预测值以及后续视锥细胞中CIN2-3的回归。还比较了通过线性阵列基因分型测试(LA),PreTect HPV-Proofer和Cobas4800检测到的HPV亚型。随访的组织病理学经过专家共识和Ki67 / p16支持。通过对后续活检中CIN2-3的存在进行不同测试,评估了HPV在LBC中的预测值,并评估了后续视锥细胞的回归。结果:Amplicor,Cobas4800和APTIMA对HPV阳性/阴性表现出良好的一致性。与其他任何方法相比,PreTect HPV-Proofer有许多差异。 Amplicor,Cobas4800和APTIMA检测CIN2-3的灵敏度非常高(96-100%),但对于PreTect HPV校样器则非常低(53%)。 Amplicor和Cobas4800的后续活检中CIN1或以下的特异性低于APTIMA,PreTect HPV-Proofer的特异性最高。洛杉矶的HPV分型在Cobas4800中为90%,但在PreTect HPV-Proofer中为70%。结论:Amplicor,Cobas4800和APTIMA给出了可比的结果,但PreTect HPV-Proofer与其他测试有所不同,灵敏度低但特异性更高。没有一种方法可以预测CIN2-3的回归。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号